Biotech China 2014

Profile Details
Robert S Kerbel
Affiliations:

University of Toronto



Sunnybrook Women's College Health Sciences Centre

 
,
Phone: 416) 480-5711
Fax: 416) 480-5884
My Blogs:
 
Age:
Bio:
 
Specialty:
Microbiology & Immunology .
 
Presented at Events Covering:
Anatomy, Antibodies, Bacteriology, Biochemistry, Biology, Biomedical Research, Biotechnology, Cancer Biology, Cell Biology, Cytokine, Genomics, Hematology, Hepatology, Immunology, Internal Medicine, Microbiology, Molecular Biology, Oncology, Pharmacology, Physiology, Stem Cells, Surgery, Thyroid, Translational Research
 
Areas of Interest:
 
Hobbies:
 
General Comments:
BSN Rank: 2 / 1762 (What's this?)
Accomplish Score: 12520
Popularity Score: 3
# in My Circle: 0
# in My Org(s): 278
We'll Post Your CV for Free!
 
 
Speaking/Presenting-Abstract/Poster at Mtg: 712 (9256 / 0)
 
Honors and Awards: 45 (450 / 0)
  • Tier I Canada Research Chair in Tumor Biology, Angiogenesis and Antiangiogenic Therapy (2001 - Present)
  • Keynote Lectureship Series (2010)
  • Keynote Lecture (2009)
 
Clinical Trial Activity: 5 (45 / 0)
  • Treatment of relapsed and refractory non-Hodgkin=s lymphoma with continuous low dose cyclophosphamide and Celebrex: a multicentre phase II study (2001)
  • Pilot study of low dose chemotherapy and cyclo-oxygenase-2 inhibitor as anti-angiogenic therapy in children with progressive or recurrent solid tumors (2001)
  • APhase II trial of continuous low dose cyclophosphamide and celecoxib in patients with progressive advanced renal cell carcinoma (2001)
 
Grant Support: 17 (153 / 0)
  • Translational studies of metronomic chemotherapy and antiangiogenic drugs for metastatic disease (2010)
  • Host cell assisted primary and metastatic tumor regrowth after chemotherapy (2009)
  • Surrogate molecular biomarkers for antiangiogenic receptor tyrosine kinase inhibitory drugs (2007)
 
Patents Pending: 2 (16 / 0)
  • Methods for enhancing the efficacy of vascular damaging agents. (2007)
  • Treatment, diagnosis and evaluation of anticancer therapy resistance in melanoma (Trp 2). (2003)
 
Journal - Editor/Reviewer: 17 (119 / 0)
  • International Journal of Cancer (2009)
  • Current Cancer Drug Targets (2006)
  • Angiogenesis (1998 - 2006)
 
Peer Reviewed Papers, Books, Chapters: 248 (1488 / 0)
  • Binding properties of epidermal growth factor receptor targeted monoclonal antibodies: factors contributing to differences in toxicity profiles (2010)
  • Human tumor xenografts that acquire resistance to metronomic cyclophosphamide chemotherapy retain sensitivity to maximum tolerated cyclophosphamide doses (2010)
  • Metronomic irinotecan therapy combined with bevacizumab for effective treatment of preclinical advanced ovarian cancer: role of SDF-1 inhibition. (2010)
 
Pre/Non Reviewed Papers, Proceedings: 248 (992 / 0)
  • Anti-Tumor Effect of CT-322 as an Adnectin Inhibitor of Vascular Endothelial Growth Factor Receptor-2. (2010)
  • Impact of UFT/cyclophosphamide metronomic chemotherapy and antiangiogenic drug therapy assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma (2010)
  • Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer (2010)
 
Membership in Professional Societies: 0 (0 / 0)
 
White Papers: 1 (0 / 0)
 
Registered on BiotechScienceNews: 1

4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.